Takeda's orteronel misses PhIII endpoint in post-chemo prostate cancer
This article was originally published in Scrip
Executive Summary
Takeda has had to unblind an international Phase III trial with its novel prostate cancer drug orteronel (TAK-700) in post-chemotherapy patients after an interim analysis showed the ELM-PC 5 (C21005) study would miss its primary endpoint of improved overall survival.